Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.
Identifieur interne : 001C05 ( Main/Exploration ); précédent : 001C04; suivant : 001C06Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.
Auteurs : Marie Fechtenbaum [France] ; Pauline Lasselin-Boyard ; Sarah Salomon ; Germain Jelin ; Florence Millot ; Franck Grados ; Patrice Fardellone ; Vincent GoëbSource :
- Pharmacology [ 1423-0313 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (administration et posologie), Antirhumatismaux (effets indésirables), Antirhumatismaux (usage thérapeutique), Femelle, Humains, Mâle, Polyarthrite rhumatoïde (traitement médicamenteux), Projets pilotes, Relation dose-effet des médicaments, Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Antirhumatismaux.
- effets indésirables : Anticorps monoclonaux humanisés, Antirhumatismaux.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antirhumatismaux.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Projets pilotes, Relation dose-effet des médicaments, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- drug therapy : Arthritis, Rheumatoid.
- Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Treatment Outcome.
Abstract
The efficacy and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) are well demonstrated. Doses of 4 and 8 mg/kg are used intravenously. The objective of our study was to report the efficacy and safety for a set of patients who had an 8 mg/kg doze of TCZ and for another set who had this treatment first at a dose of 8 followed by 4 mg/kg.
DOI: 10.1159/000445953
PubMed: 27115145
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E75
- to stream PubMed, to step Curation: 000E75
- to stream PubMed, to step Checkpoint: 000E78
- to stream Ncbi, to step Merge: 001155
- to stream Ncbi, to step Curation: 001155
- to stream Ncbi, to step Checkpoint: 001155
- to stream Main, to step Merge: 001C05
- to stream Main, to step Curation: 001C05
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.</title><author><name sortKey="Fechtenbaum, Marie" sort="Fechtenbaum, Marie" uniqKey="Fechtenbaum M" first="Marie" last="Fechtenbaum">Marie Fechtenbaum</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, CHU Amiens, Amiens, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Amiens, Amiens</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Lasselin Boyard, Pauline" sort="Lasselin Boyard, Pauline" uniqKey="Lasselin Boyard P" first="Pauline" last="Lasselin-Boyard">Pauline Lasselin-Boyard</name></author><author><name sortKey="Salomon, Sarah" sort="Salomon, Sarah" uniqKey="Salomon S" first="Sarah" last="Salomon">Sarah Salomon</name></author><author><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name></author><author><name sortKey="Millot, Florence" sort="Millot, Florence" uniqKey="Millot F" first="Florence" last="Millot">Florence Millot</name></author><author><name sortKey="Grados, Franck" sort="Grados, Franck" uniqKey="Grados F" first="Franck" last="Grados">Franck Grados</name></author><author><name sortKey="Fardellone, Patrice" sort="Fardellone, Patrice" uniqKey="Fardellone P" first="Patrice" last="Fardellone">Patrice Fardellone</name></author><author><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goëb">Vincent Goëb</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27115145</idno><idno type="pmid">27115145</idno><idno type="doi">10.1159/000445953</idno><idno type="wicri:Area/PubMed/Corpus">000E75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E75</idno><idno type="wicri:Area/PubMed/Curation">000E75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E75</idno><idno type="wicri:Area/PubMed/Checkpoint">000E78</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E78</idno><idno type="wicri:Area/Ncbi/Merge">001155</idno><idno type="wicri:Area/Ncbi/Curation">001155</idno><idno type="wicri:Area/Ncbi/Checkpoint">001155</idno><idno type="wicri:Area/Main/Merge">001C05</idno><idno type="wicri:Area/Main/Curation">001C05</idno><idno type="wicri:Area/Main/Exploration">001C05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.</title><author><name sortKey="Fechtenbaum, Marie" sort="Fechtenbaum, Marie" uniqKey="Fechtenbaum M" first="Marie" last="Fechtenbaum">Marie Fechtenbaum</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, CHU Amiens, Amiens, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Amiens, Amiens</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Lasselin Boyard, Pauline" sort="Lasselin Boyard, Pauline" uniqKey="Lasselin Boyard P" first="Pauline" last="Lasselin-Boyard">Pauline Lasselin-Boyard</name></author><author><name sortKey="Salomon, Sarah" sort="Salomon, Sarah" uniqKey="Salomon S" first="Sarah" last="Salomon">Sarah Salomon</name></author><author><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name></author><author><name sortKey="Millot, Florence" sort="Millot, Florence" uniqKey="Millot F" first="Florence" last="Millot">Florence Millot</name></author><author><name sortKey="Grados, Franck" sort="Grados, Franck" uniqKey="Grados F" first="Franck" last="Grados">Franck Grados</name></author><author><name sortKey="Fardellone, Patrice" sort="Fardellone, Patrice" uniqKey="Fardellone P" first="Patrice" last="Fardellone">Patrice Fardellone</name></author><author><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goëb">Vincent Goëb</name></author></analytic><series><title level="j">Pharmacology</title><idno type="eISSN">1423-0313</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Projets pilotes</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Projets pilotes</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) are well demonstrated. Doses of 4 and 8 mg/kg are used intravenously. The objective of our study was to report the efficacy and safety for a set of patients who had an 8 mg/kg doze of TCZ and for another set who had this treatment first at a dose of 8 followed by 4 mg/kg.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Picardie</li></region><settlement><li>Amiens</li></settlement></list><tree><noCountry><name sortKey="Fardellone, Patrice" sort="Fardellone, Patrice" uniqKey="Fardellone P" first="Patrice" last="Fardellone">Patrice Fardellone</name><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goëb">Vincent Goëb</name><name sortKey="Grados, Franck" sort="Grados, Franck" uniqKey="Grados F" first="Franck" last="Grados">Franck Grados</name><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name><name sortKey="Lasselin Boyard, Pauline" sort="Lasselin Boyard, Pauline" uniqKey="Lasselin Boyard P" first="Pauline" last="Lasselin-Boyard">Pauline Lasselin-Boyard</name><name sortKey="Millot, Florence" sort="Millot, Florence" uniqKey="Millot F" first="Florence" last="Millot">Florence Millot</name><name sortKey="Salomon, Sarah" sort="Salomon, Sarah" uniqKey="Salomon S" first="Sarah" last="Salomon">Sarah Salomon</name></noCountry><country name="France"><region name="Hauts-de-France"><name sortKey="Fechtenbaum, Marie" sort="Fechtenbaum, Marie" uniqKey="Fechtenbaum M" first="Marie" last="Fechtenbaum">Marie Fechtenbaum</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27115145
|texte= Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27115145" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |